Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure. Issue 1 (21st October 2019)

• Record Type: Journal Article
• Authors: Sarhan, Neven M.; Shahin, Mohamed H.; El Rouby, Nihal M.; El‐Wakeel, Lamia M.; Solayman, Mohamed H.; Langaee, Taimour; Khorshid, Hazem; Schaalan, Mona F.; Sabri, Nagwa A.; Cavallari, Larisa H.
• Is Part Of: Clinical and translational science. Volume 13:Issue 1(2020)
• Page Start: 195
• Page End: 203
• Publication Date: 2019-10-21
• Subjects: Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.12702
• Languages: English
• ISSNs: 1752-8054

Abstract

Abstract : This prospective cohort study evaluated the association between the renin angiotensin aldosterone system genotypes and response to spironolactone in 155 Egyptian patients with heart failure with reduced ejection fraction (HFrEF). Genotype frequencies for AGT rs699 were: CC = 16%, CT = 48%, and TT = 36%. Frequencies for CYP11B2 rs1799998 were: TT = 33%, TC = 50%, and CC = 17%. After 6 months of spironolactone treatment, change in the left ventricular ejection fraction (LVEF) differed by AGT rs699 (CC, 14.6%; TC, 7.9%; TT, 2.7%; P = 2.1E‐26), and CYP11B2 rs1799998 (TT, 9.1%; TC, 8.7%; CC, 1.4%; P = 0.0006) genotypes. Multivariate linear regression showed that the AGT rs699 and CYP11B2 rs1799998 polymorphisms plus baseline serum potassium explained 71% of variability in LVEF improvement ( P = 0.001), 63% of variability in serum potassium increase ( P = 2.25E‐08), and 39% of the variability in improvement in quality of life ( P = 2.3E‐04) with spironolactone therapy. These data suggest that AGT and CYP11B2 genotypes as well as baseline serum K are predictors of spironolactone response in HFrEF.